Clinical consideration and management of coronavirus disease 2019
Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 28(2020), 3 vom: 20. März, Seite 222-228 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Ma, K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019 novel coronavirus |
|---|
| Anmerkungen: |
Date Completed 21.04.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn50113-20200220-00056 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308914368 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308914368 | ||
| 003 | DE-627 | ||
| 005 | 20231225132750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn50113-20200220-00056 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308914368 | ||
| 035 | |a (NLM)32306656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Ma, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical consideration and management of coronavirus disease 2019 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2019 novel coronavirus | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Chen, T |e verfasserin |4 aut | |
| 700 | 1 | |a Han, M F |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, W |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Q |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology |d 1998 |g 28(2020), 3 vom: 20. März, Seite 222-228 |w (DE-627)NLM096493321 |x 1007-3418 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:3 |g day:20 |g month:03 |g pages:222-228 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn50113-20200220-00056 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 3 |b 20 |c 03 |h 222-228 | ||